Methotrexate Accord

Methotrexate, the active ingredient in Methotrexate Accord, is an antimetabolite (folate antagonist) presented as a sterile injectable solution for intraarterial, intramuscular, and intrathecal administration. It is used in the treatment of various malignancies, autoimmune disorders, and gestational trophoblastic disease in adult patients.

GNH USA supplies Methotrexate Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and regulatory requirements to ensure product integrity. Products are shipped globally with appropriate temperature controls and documentation.

Methotrexate is an antimetabolite used in oncology and autoimmune disease management.

Acute lymphoblastic leukemia: reduces leukemic cell proliferation and induces remission. Chronic lymphocytic leukemia: slows disease progression and improves survival. Non‑Hodgkin lymphoma: decreases tumor burden and prolongs remission. Psoriasis: limits skin cell overgrowth, reducing plaques. Rheumatoid arthritis: diminishes inflammatory activity and joint damage. Gestational trophoblastic disease: eradicates trophoblastic tissue and prevents recurrence.

Methotrexate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea or vomiting. - Oral ulcers or mucositis. - Fatigue or malaise. - Mild liver enzyme elevation.

Serious or Rare Side Effects: - Severe hepatotoxicity or fibrosis. - Bone marrow suppression leading to pancytopenia. - Pulmonary toxicity, including interstitial pneumonitis. - Nephrotoxicity with acute kidney injury. - Life‑threatening infections due to immunosuppression.

Before initiating therapy, clinicians should evaluate patient history, baseline labs, and potential contraindications.

Pregnancy avoidance: contraindicated in pregnancy (Category X) due to teratogenic risk. Renal function monitoring: adjust dose or avoid if severe impairment. Hepatic monitoring: perform regular liver function tests. Infection vigilance: monitor for signs of infection and advise prompt reporting. Contraception requirement: both male and female patients of reproductive potential must use effective contraception. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Methotrexate interacts with several drug classes that can modify its efficacy or toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Proton pump inhibitors (e.g., omeprazole): may raise serum levels. - Trimethoprim‑sulfamethoxazole: enhances myelosuppression.

Moderate Interactions (Monitor Closely): - Penicillins: may reduce renal clearance. - Phenytoin: can lower methotrexate concentrations. - Live vaccines: risk of severe infection; avoid concurrent use.